Incyte Bags Another Big Pharma Collaboration
By Taskin Ahmed
Pharma Deals Review: Vol 2010 Issue 1 (Table of Contents)
Published: 4 Jan-2010
DOI: 10.3833/pdr.v2010.i1.1297 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Incyte has tapped a second big pharma in as many months by signing a co-development deal worth US$755 M for its JAK1/JAK2 inhibitor, INCB 28050, in development for the treatment of rheumatoid arthritis, with Eli Lilly & Co...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS